Imugene Ltd is a biotechnology company working in cancer immunotherapy. The company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer, where the cancer is HER-2-positive. Imugene was planning a Phase Ib/II clinical study of HER-Vaxx in gastric cancer which it intended to initiate in 2016. Imugene stock is publicly traded on the Australian Securities Exchange (ASX).
Attributes | Values |
---|---|
rdf:type | |
rdfs:label |
|
rdfs:comment |
|
foaf:name |
|
name |
|
location | |
dct:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage |
|
sameAs | |
dbp:wikiPageUsesTemplate | |
foundation |
|
industry | |
key people |
|
location |
|
products |
|
type |
|
has abstract |
|
gold:hypernym | |
prov:wasDerivedFrom | |
page length (characters) of wiki page |
|
founding year |
|
industry | |
key person | |
foaf:isPrimaryTopicOf | |
is Link from a Wikipage to another Wikipage of | |
is foaf:primaryTopic of |